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Abstract The aim of this study was to assess the role of
depression as a predictor of new onset of chronic migraine
(CM) among persons with episodic migraine (EM). The
American Migraine Prevalence and Prevention (AMPP)
study followed 24,000 persons with severe headache
identified in 2004. Using random-effects logistic regres-
sion, we modeled the probability that persons with EM in
2005 or 2006 would develop CM in the subsequent year.
Depression was assessed in two ways, using a validated
questionnaire (PHQ-9 score C15) and based on self-
reported medical diagnosis. Analyses were adjusted for
multiple covariates including sociodemographics, body
mass index, headache pain intensity, headache frequency,
migraine symptom severity, cutaneous allodynia, acute
medication overuse, anti-depressant use and anxiety. Of
6,657 participants with EM in 2005, 160 (2.4 %) developed
CM in 2006. Of 6,852 participants with EM in 2006, 144
(2.2 %) developed CM in 2007. In fully adjusted models,
PHQ-9 defined depression was a significant predictor of
CM onset [odds ratio (OR) = 1.65, 95 % CI 1.12–2.45].
There was a depression-dose effect; relative to participants
with no depression or mild depression, those with moderate
(OR = 1.77, 95 % CI 1.25–2.52), moderately severe
(OR = 2.35, 95 % CI 1.53–3.62), and severe depression
(OR = 2.53, 95 % CI 1.52–4.21) were at increased risk for
the onset of CM. Among persons with EM, depression was
associated with an increased risk of CM after adjusting for
sociodemographic variables and headache characteristics.
Depression preceded the onset of CM and risk increased
with depression severity suggesting a potentially causal
role though reverse causality cannot be excluded.
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Introduction
Migraine, a chronic disorder with episodic attacks, can be
subtyped based on attack frequency into episodic migraine
(EM) or chronic migraine (CM) [1]. In EM, headache
attacks occur on \15 days/month. In CM, considered
a complication of EM, headache attacks occur on
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C15 days/month for at least 3 months [1, 2]. The popula-
tion prevalence of CM ranges from 1.3 to 2.4 % [3].
The process of developing CM from EM, sometimes
termed ‘‘transformation’’ or ‘‘progression’’ occurs in
approximately 2 % of persons with EM annually [4, 5].
Epidemiologic studies and clinical observations support a
transition model for migraine [6]. In this model, transfor-
mation is associated with various modifiable and unmodi-
fiable risk factors [4, 5]. Modifiable risk factors may
provide targets for future preventive interventions,
designed to reduce new onset of CM.
Both clinic and population-based studies have demon-
strated that, compared to EM, CM is associated with
greater migraine-related disability [7, 8], reduced quality of
life [9], increased resource utilization [8], and increased
medical and psychiatric comorbidities including depression
[10]. Epidemiologic studies estimate lifetime prevalence
rates of major depression of 5–17 % in the general US
population [11]. Migraine and depression are highly
comorbid and share a bidirectional relationship [12]. The
effect of depression on the new onset of CM in episodic
migraineurs has not been examined in longitudinal, popu-
lation-based studies.
Herein, we assess the role of depression as a predictor of
the new onset of CM in individuals with EM using data
from the AMPP study database. Our estimates of the
depression effect are adjusted for a comprehensive set of
covariates to better assess the contribution of depression
after taking potential confounders into account.
Methods
Study survey and population
The AMPP study is a two-phase, longitudinal, population-
based survey of headache epidemiology. Sampling meth-
ods and design have been described elsewhere [13].
Briefly, in phase 1, a self-administered headache screening
survey was mailed in June 2004 to a stratified random
sample of 120,000 US households. The 2004 sample
yielded data for 162,756 household members aged 12 and
older with gender-equivalent response rates. A random
sample of 24,000 adults (age 18 and older) was selected
from the 30,721 respondents reporting at least one severe
headache in the past year in the 2004 screener. This ran-
dom sample was enrolled in phase 2: an ongoing longitu-
dinal follow-up study. To be included in the current study,
respondents had to meet criteria for EM in 2005 and return
valid questionnaires in 2005, 2006, and 2007. The study
was approved by the Albert Einstein College of Medicine,
Institutional Review Board.
Headache diagnosis and case definitions
The headache module of the AMPP study includes items
that assess migraine features according to ICHD-2 criteria
[1]. The module has a sensitivity of 100 % and specificity
of 82 % for migraine diagnosis [14], and sensitivity of
93 % and specificity of 85 % for CM diagnosis [15]. EM
was defined as headache occurring \15 days/month on
average over the preceding 3 months and fulfilling ICHD-2
criteria for migraine. CM was defined as having headache
on C15 days/month averaged over the preceding 3 months
and meeting ICHD-2 criteria for migraine. The criteria
used are a variation from the ICHD-2R definition of CM
[2]. The new onset of CM (i.e., transformation) was defined
as: (1) having EM in 2005 and developing CM in 2006
and/or (2) having EM in 2006 and developing CM in 2007.
The reference groups for the two transformation events
were those who did not develop CM within the time
interval of interest and who never met criteria for CM in
the years 2005–2007.
Assessment of independent variables
Depression was measured in two ways: using a validated
questionnaire (the Patient Health Questionnaire-depression
module (PHQ-9) [16]) and based on self-reported physician
diagnosis (SRPD-Depression). The PHQ-9 provides a
validated measure of current Major Depressive Disorder
based on DSM-IV criteria [16]. The PHQ-9 assesses
symptoms and functional impairment over the preceding
2 weeks and contains nine items with four frequency
response options (scored as 0, 1, 2, and 3). A sum score is
used to categorize participants into four depression cate-
gories: none/minimal (0–4), mild (5–9), moderate (10–14),
moderately severe (15–19), and severe (20–27). A cut score
of 15 was used to define the dichotomous depression var-
iable. In models assessing the dose response for depression,
we combined none/minimal and mild into the reference
group against which moderate, moderately severe, and
severe were separately contrasted. The SRPD-depression
item assessed rates of ever being diagnosed with major
depression by a physician.
A variety of covariate adjustments were included to
assess the robustness of the depression effect and unique
contribution of the adjusting effects. Covariates included
were selected based on theoretical relevance and evidence
in the literature linking them to the emergence of CM.
Variables employed for adjustment included sociodemo-
graphic features, headache features (including attack fre-
quency, pain intensity, symptom severity and allodynia),
comorbid health conditions such as anxiety as well as
medication use.
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Sociodemographic data such as age, gender, weight,
insurance, and income were obtained via self-report. Body
mass index (BMI) was calculated using the standard for-
mula based on self-reported height and weight.
Headache features included a measure of average pain
intensity on a scale of 0–10 with 0 indicating no pain and
10 indicating the most severe pain possible [17]. Average
pain responses were dichotomized at scores C4, defining
moderate to severe pain. In addition, monthly headache
frequency in years preceding transformation to CM was
assessed by self-report. Monthly headache frequency esti-
mates were obtained by averaging self-reported 3 month
frequency values.
Migraine symptom severity was obtained from the sum
of the seven ICHD-2 migraine-defining features for
migraine without aura (unilateral pain, pulsatile pain
quality, pain intensity and pain increased by routine
physical activity as well as nausea, photophobia, and
phonophobia) plus an item assessing visual aura. The pri-
mary symptom items are coded to have the following
response options: never/rarely (0), less than half the time
(1), and half the time or more (2). The visual aura item was
coded as no (0) or yes (2). The sum of these items produces
the migraine symptom severity score, with values ranging
from 0 to 16.
Cutaneous allodynia was assessed with the 12-item
Allodynia Symptom Checklist, which includes questions
about the frequency of various allodynia symptoms asso-
ciated with headaches [18]. Total scores range from 0 to 24
with scores C3 defining the presence of allodynia.
Anxiety (SRPD-anxiety), a health condition comorbid
with depression, was addressed using self-reported medical
diagnosis, employing the same open recall period as that of
depression. Weekly alcohol consumption and smoking
behavior, two additional health conditions comorbid with
depression were assessed by self-report. Because alcohol
and smoking measures were only available in the 2006
AMPP battery, they were not included in longitudinal
analyses.
Two classes of medication use, use of anti-depressants
and medication overuse, were also examined because each
may contribute to confounding of the link between depres-
sion and transformation to CM. Our measure of anti-
depressant use was based on self-reported current use of any
anti-depressant compounds (including duloxetine, venla-
faxine, amitriptyline, nortriptyline, paroxetine, fluoxetine,
sertraline). Medication overuse was assessed using the acute
medication module, which evaluated self-reported use of
simple analgesic compounds, triptans, ergotamines, opioids,
and other compounds. Respondents met criteria for our
medication overuse definition if they used triptans, opioids,
or ergotamines 10 or more days per month, or used simple
analgesics 15 or more days per month.
Statistical analyses
Analyses were performed using SAS Version 9.2 (SAS
Institute Inc., Cary, NC, USA). We used a nominal alpha
level of 0.05 for statistical testing. Analysis proceeded in
two stages. In the first stage, descriptive analyses were
conducted characterizing unadjusted differences between
those who developed CM and those who did not from 2005
to 2006 and then for the 2006–2007 interval. Contrasts for
normally distributed variables (e.g., age, BMI) were based
on t tests. For binary variables (e.g., gender, and allodynia),
contrasts were based on Chi-square tests of the logistic
regression odds ratio (OR). For ordered categorical vari-
ables (e.g., income and PHQ-9 categories), contrasts were
based on the Chi-square test associated with the cumulative
logistic OR. Because headache frequency and weekly
alcohol use were count variables, inference for the mean
comparisons was based on Negative Binomial models.
In the second stage of analysis, two-stage logistic tran-
sition models were used to model the new onset of CM in
2006 and 2007 as a function of covariates in the preceding
year. The GLIMMIX Procedure for generalized linear
mixed models was used for estimation. We parameterized
the model using a binomial response distribution, logit
inverse link function, and constant subject-specific random
effect (detailed information on the model, estimation pro-
cedure, and code are available upon request). CM devel-
opment could be reported in 2006 or in 2007. As
depression is a risk factor whose status changes over time,
we used a lagged predictor approach. Specifically, odds of
developing CM in any subsequent year were modeled from
predictor values in the preceding year. Sociodemographics,
such as gender and income, were fixed within subject, thus
lags were not employed. Other effects, including, but not
limited to, age, BMI, headache frequency, allodynia, and
depression status were lagged.
We examined a series of four models, with the depres-
sion effect included in each. Model 1 focused on adjust-
ment for sociodemographic variables including age,
gender, income, insurance, and BMI (both a linear and
quadratic trend). Model 2 was fully adjusted by the addi-
tion of the lagged cutaneous allodynia effect and lagged
effects of SRPD-anxiety, average headache pain intensity,
headache frequency, and migraine symptom severity, use
of anti-depressant medication and medication overuse.
To elucidate the relationship between depression and
CM onset, two additional models were fit. Model 3
examined a dose–response effect of depression across
categories (moderate, moderately severe, and severe) rel-
ative to participants with none/mild levels of depressive
symptoms adjusting for sociodemographics, cutaneous
allodynia, SRPD-anxiety, and migraine pain intensity.
Model 4 included an additional adjustment for monthly
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headache day frequency and SRPD-depression in the years
preceding transformation to CM.
Because analyses were restricted to subjects contribut-
ing in each year from 2005 to 2007, missing data were not
caused by attrition, but by nonresponse to specific predic-
tors and covariates. PROC GLIMMIX does not permit
missing values on predictors, therefore, we implicitly
assume that covariate nonresponse was missing completely
at random [19]. Predictor-specific missing values were
consistent across all adjusted models and therefore a
common sample size for events and trials exists for models
contained in Tables 2 and 3 as well as all web tables.
Results
The study sample was composed of 8,078 persons who had
EM in 2005 or 2006 or both, did not have CM in 2005, and
provided follow-up data in 2006, and 2007 (Fig. 1). There
were 6,657 eligible participants with EM in 2005, and 160
of these developed CM in 2006. There were 6,852 eligible
participants with EM in 2006. Of these, 144 developed CM
in 2007. The full disposition of the analysis sample is
presented in Fig. 2. Some individuals, not eligible for
analysis for the 2005–2006 couplet due to missing data
were eligible for the 2006–2007 couplet.
We compared the baseline features in those with EM in
2005 based on outcome status [CM vs. other eligible out-
comes (control group)] in 2006 (Table 1). In unadjusted
analyses, persons with CM at follow-up in 2006 had lower
income levels, and higher rates of cutaneous allodynia,
SRPD-anxiety, pain intensity, headache frequency, migraine
symptom severity, anti-depressant use, medication overuse,
PHQ-9 total scores, PHQ-9 categories, and SRPD-depres-
sion rates, than those who did not develop CM at follow-up.
Findings were similar for the 2006–2007 transformation
event, where 2006 variables were employed as predictors for
transformation to CM in 2007 (Table 1).
Adjusted longitudinal modeling
To assess the predictors of new-onset CM in 2006 and 2007
in persons with EM in the preceding years, the two-stage
transition model was conditioned on a series of lagged and
un-lagged predictors. Depression was the predictor of pri-
mary interest in this study and remained significant in all
models (Table 2). After adjusting for sociodemographic
features (Model 1), the odds of transformation were
elevated in persons with depression (OR = 3.22; 95 %
CI 1.65–6.25). Under Model 2, which adds to Model 1
adjustments for cutaneous allodynia, SRPD-anxiety,
migraine pain intensity, monthly headache days, migraine
symptom severity, use of anti-depressants, and medication
overuse, the effect of depression on new-onset CM
remained robust and significant (OR = 1.65, 95 % CI
1.12–2.45) (for intermediate models, see Webtable 1).
To assess the influence of depression severity on risk of
transformation, we ran two models using PHQ-9-based
measures of depression severity as predictors of transfor-
mation. When omitting headache frequency and SRPD-
depression but adjusting for sociodemographics, cutaneous
allodynia, SRPD-anxiety, and migraine pain intensity
under Model 3 moderate (OR = 1.77, 95 % CI 1.25–2.52),
moderately severe (OR = 2.35, 95 % CI 1.53–3.62), and
severe depression (OR = 2.53, 95 % CI 1.52–4.21) all
significantly differed from none/mild depression in rates of
transformation. The addition of the headache days per
month covariate in Model 4 attenuated, but did not elimi-
nate, the dose-response effects on transformation for
moderately severe (OR = 1.82, 95 % CI 1.12–2.97), and
severe depression (OR = 1.81, 95 % CI 1.01–3.23) com-
pared to none/mild depression. Full details for dose–
response models are given in Table 3. Though elevated
depression remained significantly associated with trans-
formation in Model 4, the dose-response effect appeared to
asymptote once moderately severe depression manifested,
with no difference in point estimates observed between






















Fig. 1 Disposition of subjects during the study. 1 The study base:
respondents who provided data in 2005, 2006, 2007 and EM in either
2005 or 2006 or both. 2 1,921 participants with EM in 2006 but not
2005. 3 Of the 6,360 controls in 2006, 5,312 meet ICHD-2 criteria for
EM and 1,048 has other outcomes including PM and ETTH. 4 137
subjects with other outcomes were excluded because they developed
CM in 2008. 5 The EM subjects in 2006 included 5,331 with EM in
2005 and 2006, and 1,921 subjects with EM in 2006 but not 2005 for
a total of 6,852. 6 The 6,708 control subjects in 2007 included 5,212
with EM, 759 with PM, 691 with ETTH and any other outcomes.
EM episodic migraine, CM chronic migraine
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Discussion
This study demonstrates that in persons with EM, depres-
sion for 1 year is associated with the new onset of CM in
the next year. Depression, as measured by the PHQ-9,
remained a significant predictor of transformation after
adjusting for sociodemographic variables, headache fea-
tures including monthly headache day frequency, other
comorbidities and medication use. In addition, analyses
probing the dose–response effect of depression demon-
strated that the risk of CM onset increased with the severity
of depression. Though there is a large literature demon-
strating that migraine and depression are comorbid and
bidirectionally linked [10, 12, 20, 21], the influence of
depression on the clinical course of migraine has rarely
been investigated. We are not aware of comparable lon-
gitudinal population-based studies that assess the role of
depression as a risk factor for the transformation of EM to
CM. In evaluating this association, we endeavored to
identify a parsimonious set of potential confounders and
effect modifiers. We assessed candidate covariates based
on previous population-based reports [4, 5, 22, 23] and
univariate analyses in this sample.
In addition to depression, BMI, anxiety, several head-
ache features (including headache frequency, average pain
intensity, migraine symptom severity score, and allodynia)
and medication overuse all had univariate associations with
CM onset (Table 1). We also examined sociodemographic
variables including age, marital status and race as well as
medical covariates (SRPD-diabetes, SRPD-hypertension
and smoking), previously associated with migraine prog-
nosis [4, 22, 24]; these sociodemographic and medical
covariates were not predictors of CM onset in the current
study. Though alcohol consumption and smoking are
Fig. 2 The full disposition of the analysis sample. EM episodic migraine, CM chronic migraine, PM probable migraine, ETTH episodic tension-
type headache, CTTH chronic tension-type headache, epi episodic, HA headache
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associated with depression [25, 26], they were not associ-
ated with CM onset and were not included in our final
models. In a longitudinal model adjusting for sociodemo-
graphic covariates only (Model 1), depression was associ-
ated with a threefold increased risk of CM onset. In the
fully adjusted model (Model 2), the effect of depression on
CM onset, though highly significant, was substantially
attenuated. Along with depression, headache frequency,
migraine symptom severity and medication overuse
remained significant predictors of CM onset. Because the
relationships among covariates are complex, we ran a
series of nested models presented in the Webtable. The
Table 1 Characteristics of persons with EM based on outcome the next year (CM vs. other outcomes) for 2005/2006 and 2006/2007
Predictors in persons with EM
for outcomes the subsequent year













Age 47.3 (12.0) 48.4 (13.0) 0.30 48.1 (12.9) 48.7 (12.9) 0.59
Gender (female) 130 (81.3) 5,164 (81.2) 0.99 116 (87.9) 5,106 (82.0) 0.08
Income
\$22,500 49 (30.6) 1,571 (24.7) - 56 (42.4) 1,506 (24.2) -
$22,500–$39,999 34 (21.3) 1,256 (19.8) - 33 (25.0) 1,220 (19.6) -
$40,000–$59,999 25 (15.6) 1,227 (19.3) - 14 (10.6) 1,227 (19.7) -
$60,000–$89,999 35 (21.9) 1,154 (18.1) - 15 (11.4) 1,141 (18.3) -
C$90,000 17 (10.6) 1,152 (18.1) 0.03 14 (10.6) 1,134 (18.2) B0.001
Marital status (married) 4,067 (63.95) 101 (63.13) 0.831 4,291 (63.97) 80 (55.56) 0.039
Race (Caucasian) 5,497 (88.11) 148 (94.27) 0.021 5,417 (88.64) 119 (90.15) 0.589
BMI 30.3 (10.0) 29.2 (7.7) 0.08 29.5 (8.3) 29.4 (7.7) 0.9
SRPD-hypertension 1,851 (29.10) 39 (24.38) 0.194 2,121 (31.62) 54 (37.50) 0.135
SRPD-diabetes 688 (10.82) 21 (13.13) 0.355 – – –
Cutaneous allodynia 109 (68.1) 3,436 (54.0) B0.001 95 (66.0) 3,761 (56.1) 0.02
SRPD-anxiety 55 (34.4) 1,157 (18.2) B0.001 33 (25.0) 1,122 (18.0) 0.04
Pain intensity 154 (98.1) 5,834 (93.4) 0.03 136 (100) 6,281 (99.2) 1.0a
Headache frequency (days/month) 6.8 (4.3) 2.6 (2.8) B0.001 6.1 (4.4) 2.5 (2.8) B0.001
Migraine symptom score 12.6 (2.9) 11.3 (3.7) B0.001 12.7 (3.1) 11.6 (3.5) B0.001
Current smoking – – – 1,116 (16.64) 31 (21.53) 0.121
Weekly alcohol use – – – 2.93 (5.35) 2.85 (6.59) 0.879
Use of anti-depressants 1,100 (17.30) 53 (33.13) B0.001 1,116 (16.64) 33 (22.92) 0.047
Medication overuse 700 (11.01) 47 (29.38) B0.001 606 (9.03) 20 (13.89) 0.048
Depression (PHQ-9 total score) 8.76 (6.2) 5.74 (5.4) B0.001 8.1 (6.8) 5.3 (5.3) B0.001
Depression (PHQ-9 categories)
None/mild 96 (60.8) 5,043 (80.7) 94 (65.7) 5,472 (82.6)
Moderate 31 (19.6) 678 (10.9) 22 (15.4) 667 (10.1)
Moderately severe 20 (12.7) 334 (5.3) 13 (9.1) 289 (4.4)
Severe 11 (6.9) 195 (15.9) B0.001 14 (9.8) 200 (3.0) B0.001
SRPD-depression 70 (43.8) 1,519 (23.9) B0.001 63 (43.75) 1,992 (29.7) B0.001
Mean (standard deviation) was calculated for age, income, BMI, average headache pain rating, headache frequency, migraine symptom score,
weekly alcohol use and PHQ-9 total score. Proportion (percentage) was calculated was calculated for female gender, income groups, marital
status, race, hypertension, diabetes, cutaneous allodynia, SRPD-anxiety, current smoking, use of anti-depressants, medication overuse, PHQ-9
categories, and SRPD-depression SRPD: self-reported physician diagnosed. Variables: age (continuous), gender (binary, reference = male),
marital status (binary, reference = unmarried), race (binary, reference = non-Caucasian), BMI (continuous), SRPD-hypertension (binary, ref-
erence = no hypertension), SRPD-diabetes (binary, reference = no diabetes), allodynia (binary, diagnosis defined as score[3), SRPD-anxiety
(binary, with no SRPD-anxiety endorsement as reference), pain intensity (binary, defined as score[4), headache frequency (treated as a count of
headache days/month), migraine symptom score (continuous), current smoking (binary, reference = not currently smoking), weekly alcohol use
(count variable), use of anti-depressants (binary, reference = no use), medication overuse proxy (binary, reference = no medication overuse),
PHQ-9 total score (continuous), PHQ-9 categories (categorical), SRPD-depression (binary, with no SRPD-depression endorsement as reference)
a Note that because 100 % of the N = 144 who chronified in 2007 met criteria for severe average headache pain, the OR was inestimable and
therefore the p value was set to 1. This is why the upper bounds on the average headache pain rating confidence interval in Models 2–4 were so
extreme
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effects of allodynia and BMI vary in these models,
depending upon the other covariates.
We also assessed the influence of treatment on pro-
gression to CM from EM. Medication overuse was a sig-
nificant risk factor for development of CM, a finding
compatible with earlier studies [4, 5, 23, 27]. Use of anti-
depressants was not significantly associated with risk of
CM onset in our data; however, confounding by indication
may contribute to this result. That is, persons selected
for antidepressants may be at higher risk for progression
prior to treatment by virtue of the association between
depression (or factors associated with depression) and
CM onset. Antidepressant pharmacotherapy, employed in
both depression treatment and migraine prophylaxis, may
reduce the risk of progression through an effect on both
headache frequency and depression.
Though our findings indicate that persons with EM and
depression develop CM at increased rates, the causal nature
of this association remains uncertain. The process of CM
onset is likely heterogeneous. We propose three hypotheses
to account for the linkage between depression and the onset
of CM based on the approach suggested by Lipton and
Silberstein [28]: (1) depression may directly contribute to
the onset of CM, (2) depression may arise as a consequence
of escalating migraine frequency, and (3) CM and
depression may share genetic or environmental risk factors
that contribute to this association. These hypotheses should
not be considered mutually exclusive as more than one of
them may be at least partially correct.
Under the first hypothesis, depression is involved in an
as yet to be determined causal path which increases the
probability that persons with EM will progress to CM. This
possibility is supported by the development of depression
prior to the onset of CM, the depression-dose effect and the
robustness of the findings despite adjustment for many
potential confounders. In addition, the association has a
biologically plausible foundation based on central sensiti-
zation, as discussed below [29].
The relationship between cutaneous allodynia, a marker
of central sensitization, and depression has been addressed
in experimental animal and human pain studies [30, 31].
Animal studies [31] have also shown that depression may
induce hyperalgesia, another marker of central sensitiza-
tion. Patients with migraine and chronic tension-type
headaches have previously been reported to have muscular
and cutaneous hyperalgesia [32, 33]. Given the strong
association between depression and allodynia [33],
depression and CM [10] and the higher prevalence of
allodynia in CM [33], it is possible that depression facili-
tates the development of allodynia in EM which in turn
Table 2 Multivariate predictors of chronic migraine onset in persons with EM the year prior to onset




Age 0.99 (0.98–1.01) 1.00 (0.99–1.01)
Gender 0.75 (0.37–1.51) 1.03 (0.71–1.50)
Income 0.90 (0.74–1.09) 0.85 (0.76–0.95)*
Insurance 0.82 (0.41–1.61) 0.89 (0.61–1.29)
BMI (linear) 0.91 (0.80–1.04) 0.91 (0.85–0.96)*
BMI (quadratic) 1.00 (1.00–1.00) 1.00 (1.00–1.00)*
Cutaneous allodynia 1.04 (0.76–1.41)
SRPD-anxiety 1.31 (0.94–1.84)
Pain intensity (C4) 2.18 (0.67–7.13)
Headache frequency (days/month) 1.29 (1.21–1.36)*
Migraine symptom score 1.06 (1.01–1.11)*
Anti-depressant use 1.35 (0.95–1.91)
Medication overuse 1.79 (1.26–2.54)*
Depression (PHQ-9)c 3.22 (1.65–6.25)* 1.65 (1.12–2.45)*
Values are OR, 95 % CI. N = 304 (2.27 %) events out of 13,372 trials and 97.73 % non-events for both models
* Indicates that data are significant at the p \ 0.05 level or below
a Model 1: adjusted for age (continuous), gender (binary, reference = male), income (linear trend in cumulative categories), health insurance
status (binary, reference = uninsured), and BMI (continuous and quadratic)
b Model 2: adjusted for sociodemographics and for cutaneous allodynia (binary, diagnosis defined as score[3, SRPD-anxiety (binary, with no
SRPD-anxiety endorsement as reference), anti-depressant use (binary, reference = no use), medication overuse proxy (binary, reference = no
overuse), headache pain intensity (binary, no/mild pain (scores 0–3) versus combination of moderate (scores 4–6), moderately severe (scores
7–8), severe (scores 9–10), migraine symptom score (continuous), and headache frequency (headache days/month)
c Depression (PHQ-9) = dichotomous definition defined by a PHQ-9 cut score C15
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lowers the threshold for headache onset, increasing the
number of headache days [18]. In further support of this
mechanism, functional neuroimaging studies in clinical
chronic and experimental pain have demonstrated neuro-
plastic changes in the anterior cingulate cortex and the
amygdala [34]. Depression and anxiety are also associated
with increased activity in the amygdala which may con-
tribute to the activation of pain-facilitating pathways [35].
In combination, these findings support the hypothesis that
depression could cause CM onset through effects on central
sensitization.
Appropriate randomized trials to support this model
have not been conducted. In such a trial, one could treat
patients with EM and depression with an antidepressant
that did not influence headache (e.g., a selective serotonin
reuptake inhibitor or bupropion), predicting that treating
depression should prevent CM onset. The credibility of
inferences under such a design depends upon convincing
evidence that the treatment influences depression but not
migraine.
Under the second mechanism, depression may arise as a
consequence of more severe or escalating disease. The
assumption here is that escalating attack frequency, below
the level needed to meet a CM definition, may contribute
to the development of depression. Escalating headache
frequency could reduce self-efficacy creating depression
through the mechanism of learned helplessness [36]. For
inferential tests of this hypothesis to be valid, treatments
employed in an experimental design would be required to
effectively treat CM but not directly influence depression.
In a small, open label study, researchers demonstrated that
treating CM with onabotulinumtoxinA resulted not only in
reductions of headache frequency, but also improvements
in depression and anxiety, thus demonstrating that reducing
headache frequency, without treating depression directly,
leads to improvement in psychological outcomes [37].
Larger scale, randomized trial data could provide much
stronger support for this hypothesis.
Pooled longitudinal 
sample size 10898 1398 420656
OR, 1.81; 95%CI (1.01-3.23), P=0.04
OR, 1.82; 95%CI (1.12-2.97), P=0.02
OR, 1.37; 95%CI (0.93-2.04), P=0.11
Fig. 3 Dose–response relationship between severity of depression
and risk of developing new-onset CM
Table 3 Predictors of CM onset based on depression severity and SRPD-depression
Predictors Model 3 OR (95 % CI) Model 4 OR (95 % CI)
Age 1.00 (0.99–1.01) 1.00 (0.99–1.01)
Gender (female) 0.92 (0.65–1.29) 1.01 (0.70–1.46)
Income 0.85 (0.77–0.94)* 0.86 (0.77–0.96)*
BMI (linear) 0.92 (0.87–0.97)* 0.90 (0.85–0.96)*
BMI (quadratic) 1.00 (1.00–1.00)* 1.00 (1.00–1.00)*
Cutaneous allodynia 1.45 (1.11–1.91)* 1.20 (0.89–1.61)
SRPD-anxiety 1.40 (1.04–1.88)* 1.21 (0.86–1.72)
Pain intensity (C4) 2.96 (0.94–9.27) 2.39 (0.73–7.78)
Headache frequency 1.29 (1.22–1.37)*
Depression: moderate versus none/mild 1.77 (1.25–2.52)* 1.37 (0.93–2.04)
Depression: moderately severe versus none/mild 2.35 (1.53–3.62)* 1.82 (1.12–2.97)*
Depression: severe versus none/mild 2.53 (1.52–4.21)* 1.81 (1.01–3.23)*
SRPD-depressiona 1.38 (0.98–1.93)
Values are OR, 95 % CI. N = 304 (2.27 %) events out of 13,372 trials and 97.73 % non-events for both models
All models adjusted for age (continuous), gender (binary, reference = male), income (linear trend in cumulative categories), BMI (continuous
and quadratic), health insurance status (binary, reference = uninsured), cutaneous allodynia (binary, diagnosis defined as score [3), SRPD-
anxiety (binary, with no SRPD-anxiety as reference), and average headache pain intensity [no/mild pain (scores 0–3) versus combination of
moderate (scores 4–6), moderately severe (scores 7–8), and severe (scores 9–10)]. In addition, the final model was adjusted for headache days per
month preceding transformation to CM
Depression-PHQ-9 (categorical)
* Indicate data are significant at the p \ 0.05 level or below
a SRPD-depression: (binary, with no SRPD-depression endorsement as reference)
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Under our third hypothesis, CM and depression are
linked by shared genetic or environmental risk factors. For
example, variants in catecholamine genes could predispose
people to both CM and depression and account for the
linkage between them [38]. Alternatively, a persistently
stressful environment could contribute to both the devel-
opment of CM and depression [39]. Chronic stress is a well-
recognized risk factor for both depression and CM [39].
Specifically, Rivat et al. [40] found that chronic stress,
a common precursor to depression as outlined above,
increases the expression of genes governing the iNOS and
COX-2 inflammatory molecules and induces neuroinflam-
matory conditions suppressing the mechanical nociceptive
threshold thereby increasing hypersensitivity and hyperal-
gesia. Given accurate measures of any of these possible
mechanisms, mediation models could be examined in which
the association between depression and CM onset could be
tested for robustness to the intervening effect of potential
shared genetic or environmental variables.
These hypotheses seem to be reasonable explanations
for the association between depression and CM onset
observed in this study. The experimental designs and
analyses described, if undertaken, would serve to elucidate
the relative strength of each possible mechanism discussed.
This study has a number of strengths. We evaluated a
large population-based sample, followed participants lon-
gitudinally and systematically assessed both migraine and
depression using well-validated instruments. The AMPP
study diagnostic module is validated for the diagnosis of
migraine in the population [14]. In addition, our measure of
depression was based on the validated PHQ-9 assessment.
There are a number of limitations in our study.
Assessments of migraine and depression status were based
on self-reported validated questionnaires and not in-person
interviews or review of medical data. Moreover, anxiety
was assessed by self-report of having received a diagnosis
from a healthcare professional. Misclassification of expo-
sures and outcomes is possible. For example, we included
respondents meeting criteria for chronic tension-type
headache in the control group. While a legitimate transition
state for those with EM in a preceding year, the inclusion
of chronic tension-type headache in the reference group
could attenuate the degree of association between depres-
sion and transformation. However, our findings were
robust, and this effect is likely very small due to the modest
number of chronic tension-type headache respondents
observed in the reference groups for the two transformation
events (N = 14 and N = 28, respectively). Therefore, the
impact of the inclusion of chronic tension-type headache in
the reference is likely small.
This longitudinal population-based study demonstrates
the association between depression and the onset of CM.
Given that this is an observational study, we cannot
determine what role depression plays linking EM to CM.
However, given the strong association between depression
and CM onset observed here, for the sake of patients rou-
tine screening for depression should be considered, if for
no other reason than that it is a strong comorbidity with
CM onset and a complicating factor for treatment. In
addition, because we do not, as yet, have a biomarker
useful for identifying patients at risk for CM onset, given
the predictive strength of the covariates as risk factors for
CM onset, clinicians can routinely screen for depression,
allodynia, headache frequency, migraine symptom sever-
ity, and medication overuse, as markers to improve
detection of and modify treatment for at-risk patients.
Future work will focus on appropriately designed trials to
elucidate the operating mechanism linking EM, depression,
and CM onset.
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